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Letters to the editorNSAIDs and cardiovascular risk
In their article, Dr. Thomas Coffman and colleagues (Francois
et al., 2005) suggested that the hypertension seen with COX-2
inhibitors’ therapy is induced by direct suppression on PGI2 pro-
duction rather than enhanced TXA2 activity. Additionally, they in-
dicated that only enhanced TXA2 activity is responsible for a di-
rect damaging effect on the heart. While we salute their thorough
work and interesting results, we must disagree with their sug-
gestion that the cardiac end-organ complications seen with
COX-2 inhibitors can be decreased by the coadministration of
a low-dose aspirin. This has lead many major media agencies
to prematurely carry headlines, such as ‘‘Aspirin Might Prevent
Vioxx Cardiac Damage’’ (http://www.sciencedaily.com/releases/
2005/09/050914105945.htm; accessed on 9/14/2005) and
‘‘Vioxx aspirin solution suggested’’ (http://news.bbc.co.uk/2/hi/
health/4240820.stm; accessed on 9/14/2005) based on the re-
sult of this article.
The clinical and financial justification for utilizing COX-2 inhib-
itors over conventional NSAIDs is to reduce their gastrointestinal
toxicity. Large-scale studies such as CLASS (Silverstein et al.,
2000) and TARGET (Farkouh et al., 2004) have shown that the
coadministration of low-dose aspirin and a COX-2 inhibitor re-
sults in an equal incidence of GI complications as that seen
with NSAID therapy. Additionally, in the APPROVe (Bresalier
et al., 2005) study investigating the cardioprotective effects of
low-dose aspirin revealed no significant change in the overall
cardiac risk by the use of low-dose aspirin when used with pa-
tients receiving rofecoxib. Therefore, we believe that such con-
clusion by the team from North Carolina requires a reappraisal.
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1255.NSAIDs and cardiovascular risk—ReplyWe do not agree with Kotob and associates and their interpreta-
tion of the clinical trials of COX-2 inhibitors. In our view, none of
the published studies provide useful information regarding po-
tential effects of low-dose aspirin on cardiovascular risk. In the
APPROVe trial (Bresalier et al., 2005), aspirin use was not pre-
specified; interpretation of outcomes in patients taking aspirin
is therefore severely confounded by perceived risk.
As noted, in the retrospective analysis of patients taking
celecoxib with aspirin in the CLASS trial, there was no GI benefit
(Silverstein et al., 2000). However, over the full 12 month dura-
tion of CLASS, there was no significant GI protection with
celecoxib for the entire study population, irrespective of aspirin
use. In TARGET (Schnitzer et al., 2004), the only COX-2 inhibitor
trial in which aspirin use was prespecified, the GI benefit was at-
tenuated but perhaps not abolished with coincident aspirin. Fur-
thermore, the relative risk of cardiovascular events betweenCELL METABOLISM : DECEMBER 2005 $ VOL. 2 $ COPYRIGHT ª 2005lumaricoxib and naproxen was substantially narrowed in aspirin
users (Farkouh et al., 2004). While this finding is potentially con-
sistent with protection, none of the published trials including
TARGET have sufficient power to truly assess the impact of
aspirin on cardiovascular risk in COX-2 users (Topol and Falk,
2004).
Thus, in the absence of any relevant evidence from the ran-
domized controlled clinical trials, we stand by our conclusions
(Francois et al., 2005), with the caveat that the applicability of
our studies in mice to human complications of COX-2 inhibition
remains to be established.
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